☆ 4.2 Article

The effects of treatment regimen on the initial management of macular neovascularization subtypes in age-related macular degeneration

OPHTHALMOLOGICA (2023)

Related references

Note: Only part of the references are listed.

Review Ophthalmology

Characterisation of macular neovascularisation subtypes in age-related macular degeneration to optimise treatment outcomes

Thibaud Mathis et al.

Summary: This review aims to identify the common characteristics and prognoses of different subtypes of neovascular age-related macular degeneration (nAMD) and propose recommendations for tailored treatments. Multimodal imaging facilitates accurate determination of subtypes and optimizes patient management.

EYE (2023)

Add to Collection

Article Ophthalmology

Progression of macular atrophy in patients undergoing anti-vascular endothelial growth factor therapy for neovascular age-related macular degeneration

Han Joo Cho et al.

Summary: The study found significant differences in the progression of macular atrophy (MA) among neovascular age-related macular degeneration (AMD) subtypes. The risk of foveal involvement in MA was associated with baseline factors or phenotype of neovascular AMD, rather than with the frequency of anti-VEGF injections.

ACTA OPHTHALMOLOGICA (2021)

Add to Collection

Article Ophthalmology

Treat-and-extend anti-angiogenic protocol in clinical practice for patients with exudative age-related macular degeneration: Consensus of French experts

S. Baillif et al.

Summary: Optimizing treatment regimens for anti-angiogenic drugs, particularly in patients with exudative AMD, is crucial in ophthalmology practice. The Treat-and-Extend (TEE) approach is favored, with experts recommending a loading dose of 3 monthly injections and adjusting reinjection intervals in a standardized manner. Maintaining a maximum interval of 3 to 4 months and restarting monthly injections in cases of significant deterioration are also advised. Coordination of injection timing for bilateral disease is recommended using the shorter of the two intervals.

JOURNAL FRANCAIS D OPHTALMOLOGIE (2021)

Add to Collection

Article Ophthalmology

Long-term outcomes of intravitreal anti-VEGF therapies in patients affected by neovascular age-related macular degeneration: a real-life study

Paolo Corazza et al.

Summary: This study described real-life data from wet AMD patients treated with anti-VEGF drugs and found no significant differences between the three treatment groups, while overall there was a slight reduction in visual function in the patient cohort after long-term therapy.

BMC OPHTHALMOLOGY (2021)

Add to Collection

Article Biotechnology & Applied Microbiology

Different Outcomes of Anti-VEGF Treatment for Neovascular AMD according to Neovascular Sutypes and Baseline Features: 2-Year Real-Life Clinical Outcomes

Alessandro Arrigo et al.

Summary: This study evaluated the effects of anti-VEGF treatment on neovascular AMD in a real-life setting. Results showed no significant changes in BCVA at 1-year and 2-year follow-ups, but CMT was significantly reduced. Different types of macular neovascularization and baseline BCVA were found to correlate with visual outcomes.

BIOMED RESEARCH INTERNATIONAL (2021)

Add to Collection

Article Ophthalmology

Consensus Nomenclature for Reporting Neovascular Age-Related Macular Degeneration Data Consensus on Neovascular Age-Related Macular Degeneration Nomenclature Study Group

Richard F. Spaide et al.

OPHTHALMOLOGY (2020)

Add to Collection

Article Medicine, Research & Experimental

Efficacy and Safety of Intravitreal Aflibercept Treat-and-Extend Regimens in Exudative Age-Related Macular Degeneration: 52-and 96-Week Findings from ALTAIR A Randomized Controlled Trial

Masahito Ohji et al.

ADVANCES IN THERAPY (2020)

Add to Collection

Review Ophthalmology

Pachychoroid neovasculopathy: a type-1 choroidal neovascularization belonging to the pachychoroid spectrum-pathogenesis, imaging and available treatment options

Francesco Sartini et al.

INTERNATIONAL OPHTHALMOLOGY (2020)

Add to Collection

Review Ophthalmology

Trends in Real-World Neovascular AMD Treatment Outcomes in the UK

Hemal Mehta et al.

CLINICAL OPHTHALMOLOGY (2020)

Add to Collection

Article Multidisciplinary Sciences

Vascular maturity of type 1 and type 2 choroidal neovascularization evaluated by optical coherence tomography angiography

Yuyako Nakano et al.

PLOS ONE (2019)

Add to Collection

Article Ophthalmology

Extended (Every 12 Weeks or Longer) Dosing Interval With Intravitreal Aflibercept and Ranibizumab in Neovascular Age-Related Macular Degeneration: Post Hoc Analysis of VIEW Trials

Rahul N. Khurana et al.

AMERICAN JOURNAL OF OPHTHALMOLOGY (2019)

Add to Collection

Article Ophthalmology

Tolerating Subretinal Fluid in Neovascular Age-Related Macular Degeneration Treated with Ranibizumab Using a Treat-and-Extend Regimen FLUID Study 24-Month Results

Robyn H. Guymer et al.

OPHTHALMOLOGY (2019)

Add to Collection

Article Ophthalmology

Five-Year Real-World Outcomes of Occult and Classic Choroidal Neovascularization: Data From the Fight Retinal Blindness! Project

Alessandro Invernizzi et al.

AMERICAN JOURNAL OF OPHTHALMOLOGY (2019)

Add to Collection

Article Ophthalmology

DIFFERENCE IN TREATMENT OUTCOMES ACCORDING TO OPTICAL COHERENCE TOMOGRAPHY-BASED STAGES IN TYPE 3 NEOVASCULARIZATION (RETINAL ANGIOMATOUS PROLIFERATION)

Jae Hui Kim et al.

RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES (2018)

Add to Collection

Article Ophthalmology

Development and Course of Scars in the Comparison of Age-Related Macular Degeneration Treatments Trials

Ebenezer Daniel et al.

OPHTHALMOLOGY (2018)

Add to Collection

Article Ophthalmology

Consensus Definition for Atrophy Associated with Age-Related Macular Degeneration on OCT Classification of Atrophy Report 3

Srinivas R. Sadda et al.

OPHTHALMOLOGY (2018)

Add to Collection

Review Ophthalmology

Efficacy Comparison of Intravitreal Anti-VEGF Therapy for Three Subtypes of Neovascular Age-Related Macular Degeneration: A Systematic Review and Meta-Analysis

Jianqing Li et al.

JOURNAL OF OPHTHALMOLOGY (2018)

Add to Collection

Article Ophthalmology

Efficacy and Safety of Ranibizumab With or Without Verteporfin Photodynamic Therapy for Polypoidal Choroidal Vasculopathy A Randomized Clinical Trial

Adrian Koh et al.

JAMA OPHTHALMOLOGY (2017)

Add to Collection

Article Ophthalmology

Outcomes in Eyes with Retinal Angiomatous Proliferation in the Comparison of Age-Related Macular Degeneration Treatments Trials (CATT)

Ebenezer Daniel et al.

OPHTHALMOLOGY (2016)

Add to Collection

Article Ophthalmology

Geographic Atrophy and Activity of Neovascularization in Retinal Angiomatous Proliferation

Jiwon Baek et al.

INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE (2016)

Add to Collection

Article Ophthalmology

Regression of Choroidal Neovascularization Results in Macular Atrophy in Anti-Vascular Endothelial Growth Factor-Treated Eyes

Roomasa Channa et al.

AMERICAN JOURNAL OF OPHTHALMOLOGY (2015)

Add to Collection

Article Ophthalmology

Prospective Trial of Treat-and-Extend versus Monthly Dosing for Neovascular Age-Related Macular Degeneration TREX-AMD 1-Year Results

Charles C. Wykoff et al.

OPHTHALMOLOGY (2015)

Add to Collection

Article Ophthalmology

GEOGRAPHIC ATROPHY IN PATIENTS RECEIVING ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR FOR NEOVASCULAR AGE-RELATED MACULAR DEGENERATION

Luna Xu et al.

RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES (2015)

Add to Collection

Editorial Material Ophthalmology

Individualizing the intravitreal anti-VEGF dosing regimen for long-term management of neovascular AMD

K. Bailey Freund et al.

OPHTHALMIC SURGERY LASERS & IMAGING RETINA (2015)

Add to Collection

Article Medicine, General & Internal

Long-Term Visual Outcomes for a Treat and Extend Anti-Vascular Endothelial Growth Factor Regimen in Eyes with Neovascular Age-Related Macular Degeneration

Sarah Mrejen et al.

JOURNAL OF CLINICAL MEDICINE (2015)

Add to Collection

Article Ophthalmology

Baseline Predictors for Good Versus Poor Visual Outcomes in the Treatment of Neovascular Age-Related Macular Degeneration With Intravitreal Anti-VEGF Therapy

Bora Chae et al.

INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE (2015)

Add to Collection

Article Ophthalmology

The Incidence of Neovascular Subtypes in Newly Diagnosed Neovascular Age-Related Macular Degeneration

Jesse J. Jung et al.

AMERICAN JOURNAL OF OPHTHALMOLOGY (2014)

Add to Collection

Article Ophthalmology

Intravitreal Aflibercept (VEGF Trap-Eye) in Wet Age-related Macular Degeneration

Jeffrey S. Heier et al.

OPHTHALMOLOGY (2012)

Add to Collection

Article Ophthalmology

CAUSES OF UNSUCCESSFUL RANIBIZUMAB TREATMENT IN EXUDATIVE AGE-RELATED MACULAR DEGENERATION IN CLINICAL SETTINGS

Salomon Y. Cohen et al.

RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES (2012)

Add to Collection

Article Ophthalmology

GEOGRAPHIC ATROPHY IN RETINAL ANGIOMATOUS PROLIFERATION

Vikki A. McBain et al.

RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES (2011)

Add to Collection

Editorial Material Ophthalmology

Do We Need a New Classification for Choroidal Neovascularization in Age-Related Macular Degeneration?

K. Bailey Freund et al.

RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES (2010)

Add to Collection

Article Ophthalmology

A Variable-dosing Regimen with Intravitreal Ranibizumab for Neovascular Age-related Macular Degeneration: Year 2 of the PrONTO Study

Geeta A. Lalwani et al.

AMERICAN JOURNAL OF OPHTHALMOLOGY (2009)

Add to Collection

Article Ophthalmology

Ranibizumab versus Verteporfin Photodynamic Therapy for Neovascular Age-Related Macular Degeneration: Two-Year Results of the ANCHOR Study

David M. Brown et al.

OPHTHALMOLOGY (2009)

Add to Collection

Article Medicine, General & Internal

Ranibizumab for neovascular age-related macular degeneration

Philip J. Rosenfeld et al.

NEW ENGLAND JOURNAL OF MEDICINE (2006)

Add to Collection

Article Ophthalmology

Choroidal neovascularization

HE Grossniklaus et al.

AMERICAN JOURNAL OF OPHTHALMOLOGY (2004)

Add to Collection

© Peeref 2019-2024. All rights reserved.